Prognostic factors of Chronic Kidney Disease Review
Abstract
The main prognostic factors of chronic kidney disease (CKD) are discussed briefly. An analysis of randomized controlled trials reveals prognostic role of etiology and clinical features of CKD, iatrogenic factors, smoking and drug addiction. Analysis of clinical symptoms together with microalbuminuria, signs of cardiovascular involvement, chronic inflammation and malnutrition could increase the efficiency of early prognosis of CKD.
About the Author
A. Yu. Nikolaev
Department of Nephrology and Haemodialysis of the Russian Academy of Postgraduate Medical education, Ministry of Health, Moscow
Russian Federation
Russian Federation
References
1. Abiko H., Konta T., Hao Z. Factors correlated with plasma renin activiity in general Japanese population // Clin. Exp. Nephrol. 2009. Vol. 13. P. 130–137.
2. Agarwal R., Andersen M.J. Prognostic importance of clinic and home blood pressure recordings in patients with CKD // Kidney Int. 2006. Vol. 69. P. 406–411.
3. Akira S., Tekeda K. Toll-like receptor signaling // Nat. Rev. Immunol. 2004. Vol. 4. P. 499–511.
4. Andoh N.F., Bennet W.M. et al. Chronic Cyclosporine A nephrotoxicity // Curr. Opin. Nephrol. Hypertens. 1998. Vol. 7. P. 265–270.
5. Barsoum R.C. Hepatitis C virus: from entry to renal injury – facts and potential // Nephrol. Dial. Transplant. 2007. Vol. 22. P. 1840–1848.
6. Basi S., Lewis J.B. Microalbuminuria as a target to improve cardiovascular and renal outcome // Am. J. Kidney Dis. 2006. Vol. 47. P. 927–946.
7. Bianchi M.E. DAMPs, PAMPs and alarmins: all we need to know about danger // J. Leukoc. Biol. 2007. Vol. 81. P. 1–5.
8. Burke S.L., Evans R.G., Moretti J.L. Levels of renal and extrarenal sypathetic drive in AII-induced hypertension // Hypertension. 2008. Vol. 51. P. 878–883.
9. Calgar K., Vilmaz M.I., Sonmer A. ADMA, proteinuria and insulin resistance in non-diabetic stage I CKD // Kidney Int. 2006. Vol. 70. P. 781–787.
10. Calhoun D.A., Jones D., Textor S. Resistant Hypertension: diagnosis, evaluation and treatment // Circulation. 2008. Vol. 117. P. 510–526.
11. Chen J., Muntner P., Hamm L.L. The metabolic syndrome and chronic kidney disease in U.S. adults // Ann. Intern. Med. 2004. Vol. 140. P. 167–174.
12. Chung C.P., Oeser A., Avalos I. Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with SLE // Lupus. 2006. Vol. 15. P. 562–569.
13. Daugas E., Rougier J.P., Hill G. HAART-related nephropaties in HIV-infected patients // Kidney Int. 2005. Vol. 67. P. 393–403.
14. Dettmeyer R.B., Reuss J., Wollersen H. Heroin-associated nephropathy // Expert Opin. Drug Safety. 2005. Vol. 4. P. 19–28.
15. Dieplinger B., Mueller T., Kollerits B. Pro-A-type natriuretic peptide and pro-adrenomedullin predicts progression of CKD // Kidney Int. 2009. Vol. 75. P. 408–414.
16. Dunea G., Arruda J.A.L., Bakir A.A. Role of cocaine in ESRD in some hypertensive African-Americans // Am. J. Nephrol. 1995. Vol. 15. P. 5–9.
17. Elung-Jensen T., Starndgaard S., Kamper A.-L. Longitudinal observations on circadian BP variation in CKD stages 3–5 // Nephrol. Dial. Tranplant. 2008. Vol. 23. P. 2873–2878.
18. Eriksen B.O., Ingebretsen O.S. et al. The progression of CKD: a 10-year population-based study of the effect of gender and age // Kidney Int. 2006. Vol. 69. P. 375–382.
19. ESH-ESC Guidelines Committee. 2007 guidelines in the management of arterial hypertension // J. Hypertens. 2007. Vol. 25. P. 1105–1187.
20. Farbom P., Wahlstrand B., Almgren P. Interaction between renal function and microalbuminuria for cardiovascular risk in hypertension: NORDIL study // Hypertension. 2008. Vol. 52. P. 115–122.
21. Fontas E., van Leth F., Sabin C.A. Lipid profiles in HIV-infected patients receiving HAART // J. Infec. Dis. 2004. Vol. 189. P. 1056–1074.
22. Forman J.P., Brenner B.M. Hypertension and microalbuminuria: the bell tolls for thee // Kidney Int. 2006. Vol. 69. P. 22–28.
23. Fox C.S., Larson M.G., Leip E.P. Predictors of new-onset kidney disease in community-based population // JAMA. 2004. Vol. 291. P. 844–850.
24. Further M., Kiechl S., Mair A. Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population // Eur. Heart J. 2005. Vol. 26. P. 279–286.
25. Gazzaruso C., Bruno R., Gazzaniti A. Hypertension among HIV-infected patients and relationship to insulin resistance and metabolic syndrome // J. Hypertens. 2003. Vol. 21. P. 1377–1382.
26. Giles J.T., Post M., Blumenthal R.S. Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis // Nat. Clin. Pract. 2006. Vol. 2. P. 320–329.
27. Goodman W.G., London G. Vascular calcification in chronic kidney disease // Am. J. Kidney Dis. 2004. Vol. 43. P. 572–579.
28. Gupta S.K., Parker R.A., Robbins G.K. The effect of HAART on albuminuria in HIV-infected persons: result from rundomized trial // Nephrol. Dial. Transplant. 2005. Vol. 20. P. 2237–2242.
29. Hermann M., Ruschitzka F. Novel anti-inflammatory drugs in hypertension // Nephrol. Dial. Transplant. 2006. Vol. 21. P. 859–864.
30. Himmelfarb J., Stevinkel P., Ikizler T.A. The elephant of uremia: oxidant stress as an unifying concept of cardiovascular disease in uremia // Kidney Int. 2002. Vol. 62. P. 1524–1528.
31. Holmberg S.P., Moorman A.C., Williamson J.M. Protease inhibitors and cardiovascular outcomes in patients with HIV-1 // Lancet. 2002. Vol. 360. P. 1747–1748.
32. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and srtoke: a meta-analysis // JAMA. 2002. Vol. 288. P. 2015–2022.
33. Horakova M., Charvat J., Hasa J. Life-threatening renal failure caused by vasomotor nephropathy associated with NSAID // Int. J. Clin. Pharm. Res. 2005. Vol. 24. P. 117–122.
34. Hsu C.Y., McCulloch C.E., Darbinian J. Elevated BP and risk of ESRD in subjects without baseline kidney disease // Arch. Intern. Med. 2005. Vol. 165. P. 923–928.
35. Jafar T.H, Stark P.C., Schmid C.H. Progression of CKD: the role of blood pressure control, proteinuria and ACE inhibition: a patient-level mеta-analysis // Ann. Intern. Med. 2003. Vol. 139. P. 244–252.
36. Jones C.A., Francis M.E., Eberhardt M.S. Microalbuminuria in the US population // Am. J. Kidney Dis. 2002. Vol. 39. P. 445–459.
37. de Jong P.E. , Gansevoort R.T. et al. Fact or fiction of the epidemic of CKD – let us not squabble about estimated GFR only, but also focus on albuminuria // Nephrol. Dial. Transplant. 2008. Vol. 23. P. 1092–1095.
38. Kalantar-Zadeh K., Ikizler T.A., Block G. Malnutrition-Inflammation complex syndrome in dialysis patients: causes and consequence // Am. J. Kidney Dis. 2003. Vol. 53. P. 864–881.
39. Kankova K., Stejskaloba A., Hertlova M. Haplotype analysis of the RAGE gene: identification of the haplotype marker for diabetes nephropathy in type 2 diabetes mellitus // Nephrol. Dial. Transplant. 2005. Vol. 20. P. 1093–1102.
40. Keane W.F., Zhang Z., Lyle P.A. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study // Clin. J. Am. Soc. Nephrol. 2006. Vol. 1. P. 761–767.
41. Kovesdy C.P., Trivedi B.K., Kalantar-Zadeh K. Association of anemia with outcomes in men with moderate and severe chronic kidney disease // Kidney Int. 2006. Vol. 69. P. 560–564.
42. Kronborg J., Solbu M., Njolstad I. Predictors of change of estimated GFR: a population-based 7-year follow-up from Tromso study // Nephrol. Dial. Transplant. 2008. Vol. 23. P. 2818–1826.
43. Lai F.M., To K.F., Wang A.Y. Hepatitis B virus-related nephropathy and lupus nephritis // Mod. Pathol. 2000. Vol. 13. P. 166–172.
44. Lewelyn D.E., Garsia-Puig J. How different urinary albumin excretion rates can predict progression to nephropathy and the effect of the treatment in hypertensive diabetes // J. Renin Angiotensin Aldosterone System. 2004. Vol. 5. P. 141–145.
45. Liberopoulos E., Siamopoulos K., Elisaf M. Apolipoprotein E and renal disease // Am. J. Kidney Dis. 2004. Vol. 43. P. 223–233.
46. Lin J., Hu F.B., Rifai N. The association of serum lipids and inflammatory biomarkers with renal function in men with type 2 diabetes mellitus // Kidney Int. 2006. Vol. 69. P. 336–342.
47. Locatelli F., Canaud B., Eckardt K.-U. The importance of diabetic nephropathy in current nephrological practice // Nephrol. Dial. Transplant. 2003. Vol. 18. P. 1716–1725.
48. Lopez B., Gonzalez A., Hermida N. Myocardial fibrosis in CKD: potential benefits of torasemide // Kidney Int. 2008. Vol. 74. Suppl. 111. S19–S23.
49. Menon V., Greene T., Wang X. C-Reactive protein and albumin as predictors of all-cause and cardiovascular mortality in CKD // Kidney Int. 2005. Vol. 68. P. 766–772.
50. Methe H., Weis M., et al. Atherogenesis and inflammation – was Virchow right? // Nephrol. Dial. Transplant. 2007. Vol. 22. P. 1823–1827.
51. Meyers C.M., Seef L.B. Stehman-Breen C.O. Hepatitis C and renal disease: an update // Am. J. Kidney Dis. 2003. Vol. 42. P. 631–657.
52. Meyrier A., Noel L.U., Aurch P. Long-term renal tolerance of cyclosporine A treatment in adult idiopathic nephroitic syndrome // Kidney Int. 1994. Vol. 45. P. 1446–1456.
53. Molzahn M., Pommer W., De Broe M.E. Analgesic nephropathy / Oxford texbook of Clinical Nephrology/ edit. A.M. Davison, J.S. Cameron, J.P. Grunfeld. 1998. P. 1129–1146.
54. Moreland L.W., O Dell J.R. Glucocorticoids and rheumatoid arthritis. Back to the future // Arthritis Rheum. 2002. Vol. 46. P. 2553–2663.
55. Morse C.G., Kovacs J.A. Metabolic and sceletal complications of HIV infection: the price of success // JAMA. 2006. Vol. 296. P. 844–854.
56. Mukherjee D., Nissen S.E. Risk of cardiovascular events associated with selective COX-2 inhibitors // JAMA. 2001. Vol. 286. P. 954–959.
57. Nishimura M., Hashimoto T., Kobayashi H. Close association of Chlamydia pneumonia IgA seropositivity by ELISA with the presence of coronary artery stenosis in haemodialysis patientls // Nephrol. Dial. Transplant. 2005. Vol. 20. P. 1944–1950.
58. Nwankwo E., Bello A.K., El Nahas A.M. Chronic Kidney Disease: stemming the global tide // Am. J. Kidney Dis. 2005. Vol. 45. P. 201–208.
59. Odamaki M., Furuya R., Kunimara Y. Association between plasma adiponectin and visceral fat accumulation in hemodialysis patients // Nephron. 2006. Vol. 102. P. 8–13.
60. Orth S.R., Schroeder T., Ritz E. Effect of smoking on renal function in patients with type 1 and type 2 diabetes mellitus // Nephrol. Dial. Transplant. 2005. Vol. 20. P. 2414–2419.
61. Ozsoy R.C., van der Steeg W.A., Kastelein J.Y.P. Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastastin // Nephrol. Dial. Transplant. 2007. Vol. 22. P. 1578–1586.
62. Pauletto P., Rattazzi M., et al. Inflammation and hypertension: the search for a link // Nephrol. Dial. Transplant. 2006. Vol. 21. P. 850–853.
63. Pontremoli R., Leoncini G., Ravera M. Microalbuminuria, cardiovasacular and renal risk in primary hypertension // J. Am. Soc. Nephrol. 2002. Vol. 13. Suppl. 3. S169–S172.
64. Ravani P. Tripepu G., Mallberti F. ADMA predicts progression to dialysis and death in patients with CKD: a competing risks modeling approach // J. Am. Soc. Nephrol. 2005. Vol. 16. P. 2449–2455.
65. Retnakaran R., Cull C.A., Thorne K.L. Risk factors for renal dysfunction in type 2 diabetes: UK prospective dibetes study // Diabetes. 2006. Vol. 55. P. 1832–1839.
66. Rodriguez-Iturbe B., Johnson R.J. Role of inflammatory cells in the kidney in the induction and maintenance of hypertension // Nephrol. Dial. Transplant. 2006. Vol. 21. P. 260–263.
67. Roling J., Schmidt H., Fischreder M. HIV-associated renal disease and HAART-induced nephropathy // Clin. Infect. Dis. 2006. Vol. 42. P. 1488–1495.
68. Sherer Y., Shoenfeld I. Mechanisms of disease: atherosclerosis in autoimmume diseases // Nat. Clin. Pract. 2006. Vol. 2. P. 99–106.
69. Short R.A., Johnson R.J., Tuttle K.R. Uric acid, microalbuminuria and cardiovascilar disease in high-risk patients // Am. J. Nephrol. 2005. Vol. 25. P. 36–44.
70. Staessen J.A., Wang J.G., Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis // Lancet. 2001. Vol. 358. P. 1305–1315.
71. Stenvinkel P. C-reactive protein – does it promote vascular disease // Nephrol. Dial. Transplant. 2006. Vol. 21. P. 2718–2720.
72. Stewart J.H., McCredie M.R., Williams S.M. The enigma of hypertensive ESRD: observations on incidence and trends in 18 European, Canadian and Asian-Pacific populations, 1998 to 2002 // Am. J. Kidney Dis. 2006. Vol. 48. P. 183–191.
73. Stuveling E.M., Bakker S.J.L., Hillege H.L. Biochemical risk markers: a novel area for prediction of renal risk? // Nephrol. Dial. Transplant. 2005. Vol. 20. P. 497–508.
74. Tanaka H., Shiohira Y., Uezi Y. Metabolic syndrome and chronic kidney disease in Okinawa, Japan // Kidney Int. 2006. Vol. 69. P. 369–374.
75. Thomas M.C. Anemia in diabetes: marker or mediator of microvascular disease ? // Nat. Clin. Proc. Nephrol. 2007. Vol. 3. P. 20–30.
76. Tylicki L., Puttinger H., Rutkowski P. Smoking as a risk factor for renal injury in essential hypertension // Nephron. 2006. Vol. 103. P. 121–128.
77. Vanholder R., Massy Z., Argiles A. Chronic kidney disease as a cause of cardiovascular morbidity and mortality // Nephrol. Dial. Transplant. 2005. Vol. 20. P. 1048–1056.
78. Vogt L., de Zeeuw D., Woittiez A.J. Slective COX-2 inhibition reduces proteinuria in renal patients // Nephrol. Dial. Transplant. 2009. Vol. 24. P. 1182–1189.
79. Vupputuri S. Batuman V., Muntner P. The risk for mild kidney function decline associated with illicit drugs use among hypertensuve men // Am. J. Kidney Dis. 2004. Vol. 43. P. 629–635.
80. Weis M., von Scheidt W. Coronary artery disease in the transplant heart // Annual. Rev. Med. 2000. Vol. 51. P. 81–100.
81. Yokoyama H., Sone H., Oishi M. Prevalence of albuminuria and renal insufficiency in type 2 diabetes: JDDM15 study // Nephrol. Dial. Transplant. 2009. Vol. 24. P. 1212–1219.
Review
For citations:
Nikolaev A.Yu. Prognostic factors of Chronic Kidney Disease Review. Nephrology and Dialysis. 2011;13(4):396-402. (In Russ.)
Views:
9
Email this article 